Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2023 Feb 21;4(2):100916.
doi: 10.1016/j.xcrm.2023.100916. Epub 2023 Jan 25.

Cabozantinib plus durvalumab in advanced gastroesophageal cancer and other gastrointestinal malignancies: Phase Ib CAMILLA trial results

Anwaar Saeed  1 , Robin Park  2 , Junqiang Dai  3 , Raed Al-Rajabi  4 , Anup Kasi  4 , Joaquina Baranda  4 , Stephen Williamson  4 , Azhar Saeed  5 , Jacob Ripp  6 , Zachary Collins  7 , Kelly Mulvaney  8 , Molly Shugrue  8 , Jeanette Firth-Braun  8 , Andrew K Godwin  9 , Rashna Madan  10 , Milind Phadnis  3 , Weijing Sun  4
Affiliations
Clinical Trial

Cabozantinib plus durvalumab in advanced gastroesophageal cancer and other gastrointestinal malignancies: Phase Ib CAMILLA trial results

Anwaar Saeed et al. Cell Rep Med. .

Abstract

This is the phase Ib part of the phase I/II CAMILLA trial evaluating cabozantinib plus durvalumab in advanced chemo-refractory proficient mismatch repair or microsatellite stable (pMMR/MSS) gastrointestinal malignancies including gastric/gastroesophageal junction/esophageal (G/GEJ/E) adenocarcinoma, colorectal cancer (CRC), and hepatocellular carcinoma (HCC). Thirty-five patients are enrolled. There are no observed dose-limiting toxicities during dose escalation. The overall grade 3/4 treatment-related adverse event rate is 34%. Among evaluable patients (n = 30), the objective response rate (ORR) is 30%, disease control rate (DCR) 83.3%, 6-month progression-free survival (PFS) 36.7%, median PFS 4.5 months, and median overall survival (OS) 8.7 months. Responses are seen in 4 of 17, 3 of 10, and 2 of 3 patients with CRC, G/GEJ/E adenocarcinoma, and HCC, respectively. Participants with a PD-L1 combined positive score (CPS) ≥5 have numerically higher ORR, PFS, and OS. Cabozantinib plus durvalumab demonstrates a tolerable safety profile and potential efficacy in previously treated advanced pMMR/MSS gastrointestinal malignancies.

Keywords: cabozantinib; colorectal cancer; durvalumab; gastroesophageal cancer; hepatocellular carcinoma.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests A.S. reports research grants (to institution) from AstraZeneca, Bristol Myers Squibb, Merck, Clovis, Exelixis, Actuate Therapeutics, Incyte Corporation, Daiichi Sankyo, Amgen, Innovent Biologics, Dragonfly Therapeutics, KAHR Medical, and Biontech and advisory board fees from AstraZeneca, Bristol Myers Squibb, Exelixis, Pfizer, and Daiichi Sankyo. R.A.-R. reports research grants (to institution) from AstraZeneca, Bayor, Merck, Bristol Myers Squibb, Exelixis, and Eureka Therapeutics and stock ownership in Actinium Pharmaceuticals and Seagen. A.K. reports research funding (to institution) from Astellas, Tesaro, and Bavarian Nordic. J.B. reports research grants (to institution) from Astellas, Chungchun Intellicrown, Impact Therapeutics, Poseida Therapeutics, Takeda Oncology, and Genome Co. and consultant fees (to institution) from Sanofi. A.K.G. reports research funding from Predicine and VITRAC Therapeutics, is a co-founder of Sinochips Diagnostics, and serves as a scientific advisory board member to Biovica, Clara Biotech, and Sinochips Diagnostics. S.W. reports stock/other ownership in Horizon Therapeutics, Iovance Biotherapeutics, and Merus and institutional research funding from Aleon Pharma, Astellas Pharma, Bayer Health, Bristol Myers Squibb, Daiichi Sankyo, EMD Serono, Merck Serono, Nektar, Novartis, Pharmacyclics, AbbVie, Regeneron, Rogosin Institute, Sanofi, Seagen, and Sotio.

Figures

None
Graphical abstract
Figure 1
Figure 1
Swimmer plot showing the tumor response with duration by tumor type and month
Figure 2
Figure 2
Waterfall plot showing the percentage of change from baseline to nadir in sums of diameters of target lesions
Figure 3
Figure 3
Spider plot showing the percentage of change from baseline in sums of diameters of target lesions over time
See this image and copyright information in PMC

References

    1. Siegel R.L., Miller K.D., Fuchs H.E., Jemal A. Cancer statistics, 2021. CA A Cancer J. Clin. 2021;71:7–33. doi: 10.3322/caac.21654. - DOI - PubMed
    1. Reig M., Forner A., Rimola J., Ferrer-Fàbrega J., Burrel M., Garcia-Criado Á., Kelley R.K., Galle P.R., Mazzaferro V., Salem R., et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J. Hepatol. 2022;76:681–693. doi: 10.1016/j.jhep.2021.11.018. - DOI - PMC - PubMed
    1. Biller L.H., Schrag D. Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA. 2021;325:669–685. doi: 10.1001/jama.2021.0106. - DOI - PubMed
    1. Sangro B., Sarobe P., Hervás-Stubbs S., Melero I. Advances in immunotherapy for hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 2021;18:525–543. doi: 10.1038/s41575-021-00438-0. - DOI - PMC - PubMed
    1. Tan E., Sahin I.H. Defining the current role of immune checkpoint inhibitors in the treatment of mismatch repair-deficient/microsatellite stability-high colorectal cancer and shedding light on future approaches. Expet Rev. Gastroenterol. Hepatol. 2021;15:735–742. doi: 10.1080/17474124.2021.1886077. - DOI - PubMed

Publication types

MeSH terms

Supplementary concepts